GE Aerospace Stock Price, News & Analysis

The Board of Directors of GE (NYSE: GE) has declared a $0.08 per share dividend on the company's outstanding common stock. This dividend is scheduled for payment on July 25, 2022 to shareholders of record as of the close of business on June 28, 2022. The ex-dividend date is set for June 27, 2022. GE continues to focus on delivering reliable and efficient solutions while maintaining strong engagement with stakeholders.

At the SNMMI 2022 Annual Meeting, GE Healthcare unveiled advanced molecular imaging solutions for prostate cancer, including a new Solid Target Platform for increased Gallium-68 production. This marks the 500th installation of their cyclotron, enhancing access to critical radioisotopes used in PET imaging. The company emphasizes the role of theranostics in personalized cancer care, especially after FDA approvals for relevant therapies like Lutetium-177 PSMA-617. GE Healthcare aims to improve patient outcomes and facilitate dedicated theranostics centers globally.

GE Digital has achieved AWS Energy Competency status, demonstrating its expertise in leveraging AWS technology for the energy sector. This recognition highlights GE Digital’s Asset Performance Management (APM) software, designed to enhance the performance, reliability, and cost-efficiency of energy production. The APM solutions are critical as energy industries transition towards more renewable sources. The AWS partnership enables GE Digital to further support clients in achieving their energy transition goals.

GE Healthcare is enhancing cancer care through strategic collaborations, aiming to improve patient outcomes and clinical efficiency. The company has partnered with various organizations, including RaySearch and Elekta, to integrate imaging and radiation solutions. These efforts focus on precision medicine, utilizing AI and data analytics to streamline oncology treatments. Highlights include advancements in radiation therapy planning and the introduction of innovative diagnostic tools. GE Healthcare operates in a $17.7 billion market, emphasizing its commitment to multidisciplinary cancer care.

GE Healthcare and Medtronic announced the FDA 510(k) clearance and CE Mark approval for integrating their advanced Microstream™ capnography and INVOS™ regional oximetry technologies into the CARESCAPE precision monitoring platform. This collaboration aims to enhance patient outcomes by providing real-time, continuous monitoring, which helps in predicting and preventing perioperative complications. The integration supports improved clinical efficiency, safety, and quality of care, ultimately aiding clinicians in delivering personalized patient care.

GE Digital announced that Flexjet becomes the first fractional jet operator to implement Maintenance Insight, a data-driven solution aimed at enhancing aircraft maintenance. This technology helps optimize performance by identifying potential issues before they cause service disruptions, ultimately reducing maintenance costs. By analyzing real-time data from the aircraft, Flexjet can efficiently manage its fleet, reducing unplanned maintenance and carbon emissions. Flexjet aims to improve aircraft reliability and safety through this advanced analytics tool.

GE Healthcare has announced a $50 million investment in Israeli start-up Pulsenmore to enhance the adoption of homecare ultrasound solutions. This investment supports Pulsenmore's pursuit of U.S. FDA clearance and commercial expansion. Both companies will collaborate on distributing Pulsenmore’s products in Europe and developing ultrasound solutions for the growing homecare market, projected to reach $662.67 billion by 2027. The partnership aims to improve maternal health and clinical efficiency, reducing healthcare costs and in-clinic visits.

At the ISMRM 2022 Annual Meeting, GE Healthcare announced the expansion of its AIR Recon DL technology across its MR product portfolio. This AI-driven solution has already benefitted over two million patients, enhancing image quality and reducing scan times by up to 50%. AIR Recon DL aims to improve access to MR technology amid rising healthcare demands. The company showcased additional innovative solutions targeting challenges faced by specific patient groups, including neurodegenerative and pediatric patients, while emphasizing the significant efficiency gains for healthcare systems.